Insider · CIK 0002052410
Naji Gehchan
Files at KYTX (Kyverna Therapeutics, Inc.). First filing -, latest -.
In brief
Naji Gehchan files SEC Form 4 as officer at KYTX (Kyverna Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Naji Gehchan has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | KYTX Kyverna Therapeutics, Inc. | AGrant or award Common Stock | +18,000 | $0.00 | $0 | 18,000 | Mar 17, 2026 |
| Mar 13, 2026 | KYTX Kyverna Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +105,000 | $0.00 | $0 | 105,000 | Mar 17, 2026 |
| Jan 22, 2025 | KYTX Kyverna Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +425,000 | $0.00 | $0 | 425,000 | Jan 24, 2025 |
Questions about Naji Gehchan
Answered from the filings on this page, as of the latest one.
Is Naji Gehchan buying or selling?
Naji Gehchan has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Naji Gehchan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Naji Gehchan has 0.
Where does Naji Gehchan file Form 4?
Naji Gehchan has filed Form 4 at KYTX (Kyverna Therapeutics, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.